Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -51,038 | -41,470 | -28,562 | -18,176 | -45,567 |
| Depreciation Amortization | -389 | -689 | -761 | -535 | -1,253 |
| Other Working Capital | -1,053 | 3,240 | 2,539 | 2,664 | -1,048 |
| Other Operating Activity | 6,830 | 5,102 | 3,147 | 1,511 | 5,433 |
| Operating Cash Flow | $-45,650 | $-33,817 | $-23,637 | $-14,536 | $-42,435 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 4,556 | -9,802 | -9,877 | 3,413 | -61,683 |
| Investing Cash Flow | $4,556 | $-9,802 | $-9,877 | $3,413 | $-61,683 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 275 | 275 | 1 | N/A | 105,864 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -1,045 |
| Financing Cash Flow | $275 | $275 | $1 | $N/A | $104,819 |
| Beginning Cash Position | 75,840 | 75,840 | 75,840 | 75,840 | 75,139 |
| End Cash Position | 35,021 | 32,496 | 42,327 | 64,717 | 75,840 |
| Net Cash Flow | $-40,819 | $-43,344 | $-33,513 | $-11,123 | $701 |
| Free Cash Flow | |||||
| Operating Cash Flow | -45,650 | -33,817 | -23,637 | -14,536 | -42,435 |
| Free Cash Flow | -45,650 | -33,817 | -23,637 | -14,536 | -42,435 |